Angela Alexander-Bryant

Dr. Angela Alexander-Bryant


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 January 2019 in Nanomaterials
Verified
Journal Article
Open access
PDF file
BCBreanne Caffery
Breanne Caffery
Jeoung Soo LeeJeoung Soo Lee
Jeoung Soo Lee
AAAngela Alexander-Bryant
Angela Alexander-Bryant
Glioblastoma multiforme is the most common and aggressive primary brain tumor. Even with aggressive treatment including surgical resection, radiation, and chemotherapy, patient outcomes remain poor, with five-year survival rates at only 10%. Barriers to treatment include inefficient drug delivery across the blood brain barrier and development of drug resistance. Because gliomas occur due to sequential acquisition of genetic alterations, gene therapy represents a promising alternative to overcome limitations of conventional therapy. Gene or nucleic acid carriers must be used to deliver these therapies successfully into tumor tissue and have been extensively studied. Viral vectors have been evaluated in clinical trials for glioblastoma gene therapy but have not achieved FDA approval due to issues with viral delivery, inefficient tumor penetration, and limited efficacy. Non-viral vectors have been explored for delivery of glioma gene therapy and have shown promise as gene vectors for glioma treatment in preclinical studies and a few non-polymeric vectors have entered clinical trials. In this review, delivery systems including viral, non-polymeric, and polymeric vectors that have been used in glioblastoma multiforme (GBM) gene therapy are discussed. Additionally, advances in glioblastoma gene therapy using viral and non-polymeric vectors in clinical trials and emerging polymeric vectors for glioma gene therapy are discussed.

1 January 2013
Verified
Book Chapter
Closed access
AAAngela Alexander-Bryant
Angela Alexander-Bryant
WBWendy S Vanden Berg-Foels
Wendy S Vanden Berg-Foels
XWXuejun Wen
Xuejun Wen

18 December 2022 in Cancers
Verified
Journal Article
Open access
PDF file
KAKharimat Lora Alatise
Kharimat Lora Alatise
SGSamantha Gardner
Samantha Gardner
AAAngela Alexander-Bryant
Angela Alexander-Bryant
In the United States, over 100,000 women are diagnosed with a gynecologic malignancy every year, with ovarian cancer being the most lethal. One of the hallmark characteristics of ovarian cancer is the development of resistance to chemotherapeutics. While the exact mechanisms of chemoresistance are poorly understood, it is known that changes at the cellular and molecular level make chemoresistance challenging to treat. Improved therapeutic options are needed to target these changes at the molecular level. Using a precision medicine approach, such as gene therapy, genes can be specifically exploited to resensitize tumors to therapeutics. This review highlights traditional and novel gene targets that can be used to develop new and improved targeted therapies, from drug efflux proteins to ovarian cancer stem cells. The review also addresses the clinical relevance and landscape of the discussed gene targets.

30 March 2022 in Materials Today Bio
Verified
Journal Article
Open access
TSTimothy Samec
Timothy Samec
JBJessica Boulos
Jessica Boulos
SGSerena Gilmore
Serena Gilmore
AHAnthony Hazelton
Anthony Hazelton
AAAngela Alexander-Bryant
Angela Alexander-Bryant
Current delivery strategies for cancer therapeutics commonly cause significant systemic side effects due to required high doses of therapeutic, inefficient cellular uptake of drug, and poor cell selectivity. Peptide-based delivery systems have shown the ability to alleviate these issues and can significantly enhance therapeutic loading, delivery, and cancer targetability. Peptide systems can be tailor-made for specific cancer applications. This review describes three peptide classes, targeting, cell penetrating, and fusogenic peptides, as stand-alone nanoparticle systems, conjugations to nanoparticle systems, or as the therapeutic modality. Peptide nanoparticle design, characteristics, and applications are discussed as well as peptide applications in the clinical space.

1 January 2021 in Nanomedicine: Nanotechnology, Biology and Medicine
Verified
Journal Article
Closed access
EMEmily M. Miller
Emily M. Miller
TSTimothy M. Samec
Timothy M. Samec
AAAngela Alexander-Bryant
Angela Alexander-Bryant

3 June 2021 in Polymers
Verified
Journal Article
Open access
PDF file
Mohamed AteiaMohamed Ateia
Mohamed Ateia
AMAhmed S. Montaser
Ahmed S. Montaser
MAMohammad Arifuzzaman
Mohammad Arifuzzaman
MPMegan Pitz
Megan Pitz
khouloud jlassikhouloud jlassi
khouloud jlassi
DWDaniel Whitehead
Daniel Whitehead
In this study we developed electrospun cellulose acetate nanofibers (CANFs) that were loaded with a model non-steroidal anti-inflammatory drug (NSAID) (ibuprofen, Ib) and coated with poly(acrylamide) (poly-AAm) hydrogel polymer using two consecutive steps: an electrospinning process followed by photopolymerization of AAm. Coated and non-coated CANF formulations were characterized by several microscopic and spectroscopic techniques to evaluate their physicochemical properties. An analysis of the kinetic release profile of Ib showed noticeable differences due to the presence or absence of the poly-AAm hydrogel polymer. Poly-AAm coating facilitated a constant release rate of drug as opposed to a more conventional burst release. The non-coated CANFs showed low cumulative drug release concentrations (ca. 35 and 83% at 5 and 10% loading, respectively). Conversely, poly-AAm coated CANFs were found to promote the release of drug (ca. 84 and 99.8% at 5 and 10% loading, respectively). Finally, the CANFs were found to be superbly cytocompatible.